Abstract
Objectives: SIMPLIFY tested withdrawal of hypertonic saline (HS) or dornase alfa for 6 weeks in PwCF taking ETI and showed non-inferiority (compared with continuing HS or dornase alfa) in both lung function and respiratory symptom scores. Inclusion in either trial required ppFEV1 ≥60%, and the mean ppFEV1 was 97%. A pre-planned lower lung function (LLF) sub-study was conducted to test HS withdrawal in PwCF with ppFEV1 of 40–59%, hypothesizing that continuing HS is superior to discontinuing HS with respect to 6-week change in ppFEV1. Dornase alfa was not tested in the LLF sub-study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
